Exicure, Inc. (NASDAQ:XCUR) Sees Large Growth in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 31,100 shares, a growth of 72.8% from the October 15th total of 18,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.7% of the shares of the company are sold short.

Exicure Stock Up 16.5 %

XCUR stock opened at $3.18 on Friday. Exicure has a 52 week low of $1.44 and a 52 week high of $6.00. The business has a 50-day simple moving average of $2.71 and a 200 day simple moving average of $1.27.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, major shareholder Co. Ltd. Dgp bought 237,223 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was purchased at an average cost of $3.00 per share, for a total transaction of $711,669.00. Following the transaction, the insider now owns 849,223 shares in the company, valued at $2,547,669. The trade was a 38.76 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.90% of the company’s stock.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.